Margaret Nachtigall
Reproductive Endocrinology · New York, NYNPI 1023156627
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations.
Across 130 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$262
- Mayne Pharma Commercial LLC$243
- Ferring Pharmaceuticals Inc.$215
- AbbVie$211
- Astellas Pharma US Inc$194
- Therapeuticsmd, Inc.$183
- plus $1K from 16 others
What the payments were for
- Food & beverage$2,35699%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 25 | $262 |
| Mayne Pharma Commercial LLC | 17 | $243 |
| Ferring Pharmaceuticals Inc. | 10 | $215 |
| AbbVie | 11 | $211 |
| Astellas Pharma US Inc | 10 | $194 |
| Therapeuticsmd, Inc. | 8 | $183 |
| Novo Nordisk | 9 | $176 |
| Millicent US Inc | 8 | $164 |
| Exeltis, USA Inc. | 7 | $151 |
| AMAG Pharmaceuticals, Inc. | 3 | $148 |
| Avion Pharmaceuticals | 6 | $96 |
| Agile Therapeutics, Inc. | 4 | $73 |
| Lilly USA, LLC | 2 | $46 |
| Ascend Therapeutics US, LLC | 2 | $41 |
| Coopersurgical, Inc. | 1 | $32 |
| Bayer | 1 | $25 |
| Evofem Biosciences, Inc. | 1 | $25 |
| Organon | 1 | $22 |
| Merck | 1 | $22 |
| Virtus Pharmaceuticals LLC | 1 | $20 |
| Almatica Pharma LLC | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTRAROSA$125
How this compares
$2,379 in reported general payments places this provider in the 75th percentile of 176 reproductive endocrinology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeozahFezolinetant | 20 | $17,278 |
| Estradiol | 151 | $16,327 |
| ImvexxyEstradiol | 30 | $11,659 |
| PremarinEstrogens, Conjugated | 28 | $10,910 |
| DuaveeEstrogens,conj/Bazedoxifene | 46 | $10,368 |
| YuvafemEstradiol | 46 | $9,495 |
| EstringEstradiol | 14 | $7,436 |
| PremproEstrogen,con/M-Progest Acet | 20 | $4,793 |
| CrinoneProgesterone, Micronized | 13 | $4,767 |
| CombipatchEstradiol/Norethindrone Acet | 16 | $4,283 |
| Estradiol (Twice Weekly)Estradiol | 56 | $2,747 |
| DottiEstradiol | 27 | $2,050 |
| SynthroidLevothyroxine Sodium | 11 | $987 |
| ProgesteroneProgesterone, Micronized | 34 | $986 |
| Levothyroxine Sodium | 33 | $484 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin, Duavee, Estring, Prempro | $262 | $33,508108 claims |
| Astellas Pharma US IncVeozah | $194 | $17,27820 claims |
| Therapeuticsmd, Inc.Imvexxy | $183 | $11,65930 claims |
| AbbVieSynthroid | $211 | $98711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 176 reproductive endocrinology providers in New York.
Other reproductive endocrinology in New York
- Samuel WilliamsNew York$73K
- Brian LevineNew York$68K
- Lucky SekhonNew York$50K
- Eric FormanNew York$36K
- Frederick LicciardiNew York$24K
- Bat-Sheva MaslowNew York$23K
- Glenn SchattmanNew York$19K
- Tia Jackson-BeyNew York$14K
- Paula BradyNew York$12K
- David SableNew York$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.